While facilitating a process of complex clinical approval in the next two to three years for a family of new cancer drugs, Genentech must develop a plan for long-term capacity for a large class of new anticancer drugs. To add to the complexity and uncertainty is the fact that the deadline for the planning, construction and certification of a new installation, in addition to the large $ 600 million five years. Also, make sure that the best process technology is integrated into the new plant makes the task facing David Ebersman, senior vice president of product operations, and its management team a huge task. Marcos Ebersman issues and face equipment and describes the approach to date.
by
Daniel C. Snow,
Steven C. Charron
Alison Berkley Wagonfeld
Source: Harvard Business School
27 pages.
Date Posted: November 22, 2005. Prod #: 606052-PDF-ENG
Genentech – Case capacity planning solutions
Related Case Solutions:
RESEARCH ANALYSIS
LESLIE BRINKMAN AT VERSUTIA CAPITAL
Hexcel Turnaround
Patel Food and Chemicals Private Limited (B)
Tenova: Mining for Growth in Economic Crisis
The Changing of the Guard: Planning for Succession at Madison Childrens Foundation (B)
Motorola in China: Failure of Success
APPLE INC, 2012
Outburst at ABCO
Cree Inc.: An Update